Palbociclib, also known as Ibrance, is a drug developed by Pfizer for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. It works by inhibiting the activity of certain proteins involved in cell division, thus slowing down the growth of cancer cells.
Pfizer Powerhouse: Unveiling the Secrets of a Pharma Giant - Are You Up for the Challenge?